Desloratadine, an FDA-approved cationic amphiphilic drug, inhibits SARS-CoV-2 infection in cell culture and primary human nasal epithelial cells by blocking viral entry

The 2019 global coronavirus (COVID-19) pandemic has brought the world to a grinding halt, highlighting the urgent need for therapeutic and preventive solutions to slow the spread of emerging viruses. The objective of this study was to assess the anti-SARS-CoV-2 effectiveness of 8 FDA-approved cation...

Descripción completa

Detalles Bibliográficos
Autores principales: Morin-Dewaele, Margot, Bartier, Sophie, Berry, François, Brillet, Rozenn, López-Molina, Dennis Salomón, Nguyễn, Công Trung, Maille, Pascale, Sereno, Kevin, Nevers, Quentin, Softic, Laurent, Vaugeois, Jean-Marie, Louis, Bruno, Bequignon, Emilie, Bruscella, Patrice, Coste, André, Pawlotsky, Jean-Michel, Jamain, Stéphane, Ahmed-Belkacem, Abdelhakim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9726831/
https://www.ncbi.nlm.nih.gov/pubmed/36473907
http://dx.doi.org/10.1038/s41598-022-25399-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9726831/
https://www.ncbi.nlm.nih.gov/pubmed/36473907
http://dx.doi.org/10.1038/s41598-022-25399-5

Ejemplares similares